Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial
<p><h4>Background</h4></p> <p>Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vi...
Main Authors: | Taylor, WRJ, Thriemer, K, von Seidlein, L, Yuentrakul, P, Assawariyathipat, T, Assefa, A, Auburn, S, Chand, K, Chau, NH, Cheah, PY, Dong, LT, Dhorda, M, Degaga, TS, Devine, A, Ekawati, LL, Fahmi, F, Hailu, A, Hasanzai, MA, Hien, TT, Khu, H, Ley, B, Lubell, Y, Marfurt, J, Mohammad, H, Moore, KA, Naddim, MN, Pasaribu, AP, Pasaribu, S, Promnarate, C, Rahim, AG, Sirithiranont, P, Solomon, H, Sudoyo, H, Sutanto, I, Thanh, NV, Tuyet-Trinh, NT, Waithira, N, Woyessa, A, Yamin, FY, Dondorp, A, Simpson, JA, Baird, JK, White, NJ, Day, NP, Price, RN |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2019
|
Similar Items
-
Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency
by: Taylor, WRJ, et al.
Published: (2023) -
Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.
by: Walter R J Taylor, et al.
Published: (2023-09-01) -
The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial
by: Thriemer, K, et al.
Published: (2023) -
Primaquine for plasmodium vivax malaria treatment – authors' reply
by: Price, RN, et al.
Published: (2020) -
Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens
by: Abreha, T, et al.
Published: (2015)